<p>/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，提醒投资者针对 MoonLake Immunotherapeutics（“MoonLake” 或 “公司”）（NASDAQ: MLTX）提起的集体诉讼，因其违反了 1934 年证券交易法第 10(b) 条和第 20(a) 条以及美国证券交易委员会制定的第 10b-5 条规则。</p>
<p>在 2024 年 3 月 10 日至 2025 年 9 月 29 日之间购买公司证券的投资者（“集体诉讼期间”），鼓励在 2025 年 12 月 15 日之前与本事务所联系。</p>
<p>如果您是遭受损失的股东，请点击这里参与。</p>
<p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址为 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话 310-301-3335，免费讨论您的权利。您也可以通过本事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
<p>本案的集体尚未获得认证，在认证之前，您并未由律师代表。如果您选择不采取任何行动，您可以保持缺席集体成员身份。</p>
<p>根据投诉，公司向市场发布了虚假和误导性声明。MoonLake 误导市场其药物候选者 sonelokimab（SLK）优于其他单克隆抗体。公司在明知其对其他治疗没有证明优势的情况下，持续宣传其优越性。公司公布了 SLK 的第三阶段试验结果，分析师称其为 “灾难性结果”，导致其股价几乎损失了 90% 的价值。基于这些事实，公司在集体诉讼期间的公开声明是虚假且具有实质性误导性的。当市场了解到 MoonLake 的真相时，投资者遭受了损失。</p>
<p>加入本案以追回您的损失</p>
<p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
<p>本新闻稿在某些司法管辖区可能被视为律师广告，依据适用法律和伦理规则。</p>
<p><strong>联系方式：</strong></p>
<p>Schall 律师事务所</p>
<p>Brian Schall, Esq.,</p>
<p>www.schallfirm.com</p>
<p>办公室：310-301-3335</p>
<p>[email protected]</p>
<p>来源：Schall 律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE1Jk5ld3NJdGVtSWQ9TEE0NzE5NiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTUwMzI1UFJfTkVXU19VU1BSX19fX19MQTQ3MTk2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE1Jk5ld3NJdGVtSWQ9TEE0NzE5NiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTUwMzI1UFJfTkVXU19VU1BSX19fX19MQTQ3MTk2"/></p>

MLTX

<p>Schall 律师事务所已对 MoonLake Immunotherapeutics 提起集体诉讼，指控其证券欺诈，声称关于其药物候选者 sonelokimab 的声明虚假且具有误导性。鼓励在 2024 年 3 月 10 日至 2025 年 9 月 29 日期间购买股票的投资者在 2025 年 12 月 15 日前加入诉讼。诉讼声称 MoonLake 的公开声明具有误导性，导致投资者遭受重大损失</p>

<p>, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (&#34;MoonLake&#34; or &#34;the Company&#34;) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，提醒投资者针对 MoonLake Immunotherapeutics（“MoonLake” 或 “公司”）（NASDAQ: MLTX）提起的集体诉讼，因其违反了 1934 年证券交易法第 10(b) 条和第 20(a) 条以及美国证券交易委员会制定的第 10b-5 条规则。</p>
</div><p>Investors who purchased the Company's securities between March 10, 2024 and September 29, 2025, inclusive (the &#34;Class Period&#34;), are encouraged to contact the firm before December 15, 2025.</p>
<div class="lb-trans"><p>在 2024 年 3 月 10 日至 2025 年 9 月 29 日之间购买公司证券的投资者（“集体诉讼期间”），鼓励在 2025 年 12 月 15 日之前与本事务所联系。</p>
</div><p>If you are a shareholder who suffered a loss, click here to participate.</p>
<div class="lb-trans"><p>如果您是遭受损失的股东，请点击这里参与。</p>
</div><p>We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].</p>
<div class="lb-trans"><p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址为 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话 310-301-3335，免费讨论您的权利。您也可以通过本事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
</div><p>The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>
<div class="lb-trans"><p>本案的集体尚未获得认证，在认证之前，您并未由律师代表。如果您选择不采取任何行动，您可以保持缺席集体成员身份。</p>
</div><p>According to the Complaint, the Company made false and misleading statements to the market. MoonLake misled the market about its drug candidate, sonelokimab (SLK), which it claimed was superior to other monoclonal antibodies. The Company consistently touted its superiority while knowing it had no proven advantages over other treatments. The Company announced the results of a Phase 3 trial of SLK, disclosing what analysts labeled a &#34;disastrous result,&#34; leading to its shares losing almost 90% of their value. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about MoonLake, investors suffered damages.</p>
<div class="lb-trans"><p>根据投诉，公司向市场发布了虚假和误导性声明。MoonLake 误导市场其药物候选者 sonelokimab（SLK）优于其他单克隆抗体。公司在明知其对其他治疗没有证明优势的情况下，持续宣传其优越性。公司公布了 SLK 的第三阶段试验结果，分析师称其为 “灾难性结果”，导致其股价几乎损失了 90% 的价值。基于这些事实，公司在集体诉讼期间的公开声明是虚假且具有实质性误导性的。当市场了解到 MoonLake 的真相时，投资者遭受了损失。</p>
</div><p>Join the case to recover your losses</p>
<div class="lb-trans"><p>加入本案以追回您的损失</p>
</div><p>The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.</p>
<div class="lb-trans"><p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>本新闻稿在某些司法管辖区可能被视为律师广告，依据适用法律和伦理规则。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>The Schall Law Firm</p>
<div class="lb-trans"><p>Schall 律师事务所</p>
</div><p>Brian Schall, Esq.,</p>
<div class="lb-trans"><p>Brian Schall, Esq.,</p>
</div><p>www.schallfirm.com</p>
<div class="lb-trans"><p>www.schallfirm.com</p>
</div><p>Office: 310-301-3335</p>
<div class="lb-trans"><p>办公室：310-301-3335</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE The Schall Law Firm</p>
<div class="lb-trans"><p>来源：Schall 律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE1Jk5ld3NJdGVtSWQ9TEE0NzE5NiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTUwMzI1UFJfTkVXU19VU1BSX19fX19MQTQ3MTk2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA47196&amp;Transmission_Id=202512150325PR_NEWS_USPR_____LA47196&amp;DateId=20251215"/></p>

MLTX 投资者有机会与 Schall 律师事务所共同主导 MoonLake Immunotherapeutics 的证券欺诈诉讼